Zynerba Pharma (NASDAQ:ZYNE) Rating Kept

H.C. Wainwright have a $30.0 target price per share on the stock. The target price per share gives a potential upside of 41.78 % from Zynerba Pharma (NASDAQ:ZYNE)’s previous close. This rating was disclosed to clients in an analyst note on Tuesday morning.

NASDAQ:ZYNE is right now trading 7.68% higher at $21.16 as of 12:00 AM New York time. Zynerba Pharma’s stock is 0% over the past 200 days. It has underperformed the S&P500 Index, which has increased 10.69% over the same time.

Zynerba Pharma (NASDAQ:ZYNE) Profile

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome.

Zynerba Pharma (NASDAQ:ZYNE) traded up 7.68% on 28 March, hitting $21.16. A total of 200 shares of the company’s stock traded hands. This is down from average of 412,290 shares. Zynerba Pharma has a 52 week low of $6.02 and a 52 week high of $23.75. The company has a market cap of $271.01 million and a P/E ratio of 0.

Get the latest Zynerba Pharma (NASDAQ:ZYNE) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Analysts at H.C. Wainwright Reiterated their Buy rating for Zynerba Pharma (NASDAQ:ZYNE) with $30.0 PT appeared first on Octafinance.